Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus–Infected Hepatocytes During Interferon Administration

Keisuke Fukutomi, Hayato Hikita, Kazuhiro Murai, Tasuku Nakabori, Akiyoshi Shimoda, Makoto Fukuoka, Takuo Yamai, Yuichiro Higuchi, Kei Miyakawa, Hiroshi Suemizu, Akihide Ryo, Ryoko Yamada, Takahiro Kodama, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara – 24 August 2021 – Capsid allosteric modulators (CAMs) inhibit the encapsidation of hepatitis B virus (HBV) pregenomic RNA (pgRNA), which contains a pathogen‐associated molecular pattern motif.

WNT7B Regulates Cholangiocyte Proliferation and Function During Murine Cholestasis

Karis Kosar, Pamela Cornuet, Sucha Singh, Elizabeth Lee, Silvia Liu, Jenesis Gayden, Toshifumi Sato, Zachary Freyberg, Gavin Arteel, Kari Nejak‐Bowen – 24 August 2021 – We previously identified an up‐regulation of specific Wnt proteins in the cholangiocyte compartment during cholestatic liver injury and found that mice lacking Wnt secretion from hepatocytes and cholangiocytes showed fewer proliferating cholangiocytes and high mortality in response to a 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine (DDC) diet, a murine model of primary sclerosing cholangitis.

Induced Pluripotent Stem Cells From Subjects With Primary Sclerosing Cholangitis Develop a Senescence Phenotype Following Biliary Differentiation

Nidhi Jalan‐Sakrikar, Thiago M. De Assuncao, Amaia Navarro‐Corcuera, Feda H. Hamdan, Lorena Loarca, Lindsey A. Kirkeby, Zachary T. Resch, Steven P. O’Hara, Brian D. Juran, Konstantinos N. Lazaridis, Charles B. Rosen, Julie K. Heimbach, Timucin Taner, Vijay H. Shah, Nicholas F. LaRusso, Robert C. Huebert – 24 August 2021 – Primary sclerosing cholangitis (PSC) is a chronic fibroinflammatory disease of the biliary tract characterized by cellular senescence and periportal fibrogenesis.

Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH

Christian L. Horn, Amilcar L. Morales., Christopher Savard, Geoffrey C Farrell, George N. Ioannou – 23 August 2021 – The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and NAFLD‐related cirrhosis in the United States and globally highlights the need to better understand the mechanisms causing progression of hepatic steatosis to fibrosing steatohepatitis and cirrhosis in a small proportion of patients with NAFLD.

Cognitive Impairment and Physical Frailty in Patients With Cirrhosis

Kacey Berry, Andres Duarte‐Rojo, Joshua D. Grab, Michael A. Dunn, Brian J. Boyarsky, Elizabeth C. Verna, Matthew R. Kappus, Michael L. Volk, Mara McAdams‐DeMarco, Dorry L. Segev, Daniel R. Ganger, Daniela P. Ladner, Amy Shui, Monica A. Tincopa, Robert S. Rahimi, Jennifer C. Lai, from the Multi‐Center Functional Assessment in Liver Transplantation (FrAILT) Study – 23 August 2021 – Physical frailty and impaired cognition are common in patients with cirrhosis.

Western Diet Changes Gut Microbiota and Ameliorates Liver Injury in a Mouse Model with Human‐Like Bile Acid Composition

Junichi Iwamoto, Akira Honda, Teruo Miyazaki, Tadakuni Monma, Hajime Ueda, Yukio Morishita, Sho‐ichiro Yara, Takeshi Hirayama, Tadashi Ikegami – 23 August 2021 – Western‐style high‐fat/high‐sucrose diet (HFHSD) changes gut microbiota and bile acid (BA) profiles. Because gut microbiota and BAs could influence each other, the mechanism of changes in both by HFHSD is complicated and remains unclear. We first aimed to clarify the roles of BAs in the HFHSD‐induced change of gut microbiota. Then, we studied the effects of the changed gut microbiota on BA composition and liver function.

Pretransplant Intensive Care Unit Management and Selection of Grade 3 Acute‐on‐Chronic Liver Failure Transplant Candidates

Baptiste Michard, Thierry Artzner, Mathilde Deridder, Camille Besch, Pietro Addeo, Vincent Castelain, Max Guillot, Marie‐Line Harlay, Jean‐Etienne Herbrecht, Ralf Janssen Langenstein, Maleka Schenck, Philippe Bachellier, Francis Schneider, François Faitot – 23 August 2021 – The aim of this study is to report on the liver transplantation (LT) activity and posttransplant outcome, over time, of patients with grade 3 acute‐on‐chronic liver failure (ACLF‐3) in a single transplant center performing a large number of LTs for patients with ACLF‐3.

Subscribe to